Want to see KROS full AI Analyst Report?

Keros Therapeutics (KROS) Price & Analysis

371 Followers

KROS Stock Chart & Stats

$11.12

$0.28(2.78%)

At close: Jul 27 4:00 PM EDT

$11.12

$0.28(2.78%)

Day’s Range― - ―

52-Week Range$9.69 - $22.55

Previous CloseN/A

Volume34.91K

Average Volume (3M)182.42K

Market Cap

$219.29M

Enterprise Value-$30.02M

Total Cash (Recent Filing)$257.61M

Total Debt (Recent Filing)$15.72M

Price to Earnings (P/E)―

Beta1.33

Next Earnings

Nov 11, 2026

EPS Estimate

-0.94

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-3.70

Shares Outstanding19,827,188

10 Day Avg. Volume174,714

30 Day Avg. Volume182,417

Financial Highlights & Ratios

PEG Ratio-0.06

Price to Book (P/B)2.50

Price to Sales (P/S)3.11

P/FCF Ratio7.15

Enterprise Value/Market Cap-0.14

Enterprise Value/Revenue-2.00

Enterprise Value/Gross Profit-2.11

Enterprise Value/Ebitda0.36

Forecast

1Y Price Target

$18.80

Price Target Upside69.06% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering6

EPS Forecast (FY)-5.54

Revenue Forecast (FY)$15.56M

Bulls Say, Bears Say

Bulls Say

Takeda Partnership And Milestone PotentialThe Takeda license provides external validation and reduces the funding burden of advancing elritercept through late-stage development. The $20 million milestone, prior $200 million upfront payment, potential additional milestones, and royalties create meaningful partnership-supported financial and commercial optionality.

Pipeline Advancing Into Clinical DevelopmentAdvancing rinvatercept into a Phase 2 DMD study expands Keros’s clinical pipeline beyond hematologic disorders and tests a differentiated TGF-beta pathway approach in an area with substantial unmet need. Multiple clinical programs can broaden future opportunities if efficacy and safety are demonstrated.

Low Leverage And Substantial Equity BaseThe low-debt balance sheet gives Keros greater flexibility to fund clinical development and absorb periods of operating volatility than a highly leveraged biotechnology company. Its substantial equity and asset base provide financial capacity while programs advance toward potential milestones or commercialization.

Bears Say

Sharp TTM Revenue Decline And Renewed LossesThe reversal from strong 2025 results to materially lower TTM revenue and large losses shows that current earnings power is not yet durable. Dependence on milestone-style or non-recurring revenue makes results difficult to predict and increases the financial consequences of development delays.

Persistent Cash Burn Outside A Single Strong YearRecurring negative cash generation means Keros may need future financing, partnership proceeds, or other capital sources to sustain its R&D programs. Although 2025 was strong, the broader history and renewed TTM burn indicate that internal funding capacity remains inconsistent over the next several quarters.

Chief Financial Officer TransitionA CFO resignation creates a period of leadership transition in financial reporting, planning, and capital allocation. Management stated the departure was voluntary and unrelated to accounting or operational disagreements, but the interim appointment and search still introduce execution and continuity risk.

Keros Therapeutics News

Keros Therapeutics to receive $20M development milestone payment from Takeda

Keros Therapeutics (KROS) announced that it expects to receive a $20 million development milestone payment under the terms...

22d ago

TAK

KROS

Keros announces first patient dosed in Phase 2 trial of rinvatercept

Keros Therapeutics (KROS) announced that the first patient was dosed in the Phase 2 clinical trial of rinvatercept...

23d ago

KROS

Keros Therapeutics Advances DMD Trial for KER-065, Keeping Rare Disease Upside in Play

Keros Therapeutics, Inc. ($KROS) announced an update on their ongoing clinical study. The study “A Multicenter, Phase 2,...

20d ago

KROS

Keros Therapeutics earns milestone for Phase 3 myelofibrosis trial

The latest update is out from Keros Therapeutics ( ($KROS) ). On September 29, 2026, Keros Therapeutics announced...

22d ago

KROS

Keros Begins Phase 2 Rinvatercept Trial in DMD

Keros Therapeutics ( ($KROS) ) just unveiled an announcement. On September 28, 2026, Keros Therapeutics announced that it...

23d ago

KROS

Keros Therapeutics files $350M mixed securities shelf

16:04 EDT Keros Therapeutics (KROS) files $350M mixed securities shelf Published first on TheFly – the ultimate source...

1M ago

KROS

Keros Therapeutics Announces Share Repurchase Authorization Program

Keros Therapeutics ( ($KROS) ) just unveiled an announcement. On September 8, 2026, Keros Therapeutics announced that its...

1M ago

KROS

Keros Therapeutics announces $5M share repurchase program after Takeda payment

Keros Therapeutics (KROS) announced that its board of directors has approved a $5M share repurchase program of the...

1M ago

TAK

KROS

Keros Therapeutics price target lowered to $17 from $20 at BofA

BofA lowered the firm’s price target on Keros Therapeutics (KROS) to $17 from $20 and keeps a Neutral...

2M ago

KROS

Hold Rating Maintained as Pipeline Progress Offsets Long-Term Uncertainty; Price Target Reaffirmed at $16

In a report released today, Yun Zhong from Wedbush maintained a Hold rating on Keros Therapeutics, with a...

3M ago

KROS

Keros Therapeutics price target lowered to $18 from $20 at Wells Fargo

Wells Fargo analyst Benjamin Burnett lowered the firm’s price target on Keros Therapeutics (KROS) to $18 from $20...

3M ago

KROS

Keros Therapeutics price target lowered to $23 from $30 at Leerink

Leerink lowered the firm’s price target on Keros Therapeutics (KROS) to $23 from $30 and keeps an Outperform...

3M ago

KROS

Keros updates TGF-β pipeline strategy in new presentation

Keros Therapeutics ( ($KROS) ) just unveiled an announcement. On August 3, 2026, Keros Therapeutics updated its corporate...

3M ago

KROS

Keros Therapeutics reports Q2 EPS ($1.45), consensus ($1.24)

“We are excited to have initiated our Phase 2 clinical trial evaluating the treatment of rinvatercept in patients...

3M ago

KROS

KROS FAQ

What was Keros Therapeutics’s price range in the past 12 months?

Keros Therapeutics lowest stock price was $9.69 and its highest was $22.55 in the past 12 months.

What is Keros Therapeutics’s market cap?

Keros Therapeutics’s market cap is $219.29M.

When is Keros Therapeutics’s upcoming earnings report date?

Keros Therapeutics’s upcoming earnings report date is Nov 11, 2026 which is in 21 days.

How were Keros Therapeutics’s earnings last quarter?

Keros Therapeutics released its earnings results on Aug 03, 2026. The company reported -$1.45 earnings per share for the quarter, missing the consensus estimate of -$1.34 by -$0.11.

Is Keros Therapeutics overvalued?

According to Wall Street analysts Keros Therapeutics’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Keros Therapeutics pay dividends?

Keros Therapeutics does not currently pay dividends.

What is Keros Therapeutics’s EPS estimate?

Keros Therapeutics’s EPS estimate is -0.94.

How many shares outstanding does Keros Therapeutics have?

Keros Therapeutics has 19,827,188 shares outstanding.

What happened to Keros Therapeutics’s price movement after its last earnings report?

Keros Therapeutics reported an EPS of -$1.45 in its last earnings report, missing expectations of -$1.34. Following the earnings report the stock price went up 1.385%.

Which hedge fund is a major shareholder of Keros Therapeutics?

Currently, no hedge funds are holding shares in KROS

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Keros Therapeutics Stock Smart Score

Neutral

Fundamentals

Return on Equity

-21.40%

Trailing 12-Months

Asset Growth

-62.02%

Trailing 12-Months

Learn more about TipRanks Smart Score

Top Smart Score Stocks >

Company Description

Keros Therapeutics

Keros Therapeutics, Inc., a biopharmaceutical entity in the clinical development phase, is focused on pioneering and commercializing innovative therapies for individuals afflicted by hematological and musculoskeletal conditions that currently lack adequate treatment options. Its flagship protein therapeutic, KER-050, is being advanced to address diminished blood cell counts (cytopenias), specifically anemia and thrombocytopenia, in patients diagnosed with myelodysplastic syndromes and myelofibrosis. Furthermore, the company is progressing KER-047, a small molecule designed to combat anemia, which is presently undergoing Phase 1 clinical evaluation. Another small molecule, KER-012, is also in Phase 1 clinical trials for treating ailments characterized by bone degeneration, such as osteoporosis and osteogenesis imperfecta, alongside pulmonary arterial hypertension. Founded in 2015, the firm maintains its principal operations in Lexington, Massachusetts.

Keros Therapeutics (KROS) Earnings & Revenues

Historic Earnings Reports

KROS Stock 12 Month Forecast

Average Price Target

$18.80

▲(69.06% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"9":"$9","24":"$24","12.75":"$12.75","16.5":"$16.5","20.25":"$20.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":23,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$23.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":18.8,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$18.80</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":16,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$16.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[9,12.75,16.5,20.25,24],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2026","6":"Apr<br/>2026","9":"Jul<br/>2026","12":"Oct<br/>2026","25":"Oct<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,11.26,12.163076923076924,13.066153846153846,13.96923076923077,14.872307692307693,15.775384615384615,16.67846153846154,17.58153846153846,18.484615384615385,19.38769230769231,20.29076923076923,21.193846153846152,22.096923076923076,{"y":23,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,11.26,11.84,12.42,13,13.58,14.16,14.74,15.32,15.9,16.48,17.060000000000002,17.64,18.22,{"y":18.8,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,11.26,11.624615384615385,11.989230769230769,12.353846153846154,12.718461538461538,13.083076923076923,13.447692307692307,13.812307692307693,14.176923076923076,14.541538461538462,14.906153846153845,15.27076923076923,15.635384615384616,{"y":16,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":15.28,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.22,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.18,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":20.36,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.4,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.91,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.69,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.49,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.9,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.88,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.07,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.07,"date":1788220800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.26,"date":1790812800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >